Jeanny Aragon-Ching, MD
Medical Oncology · Falls Church, VANPI 1376701946
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 23.7%. Reporting peaked in 2022 at $41,457 and has fallen 85.8% since, to $5,885 in 2025. Among medical oncology clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 149 payments — averaging $1302.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$46K
- EMD Serono, Inc.$21K
- Pfizer$19K
- Seagen Inc.$17K
- Astellas Pharma US Inc$16K
- Merck$13K
- plus $62K from 14 others
Across 1,140 payments — averaging $8038.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$6.4M
- Bayer$806K
- Seagen Inc.$669K
- E.r. Squibb & Sons, L.L.C.$542K
- Pfizer$334K
- Janssen Research & Development, LLC$226K
- plus $196K from 5 others
What the payments were for
- Consulting fees$94,31449%
- Speaking & faculty fees$88,54746%
- Travel & lodging$6,1903%
- Food & beverage$2,5691%
- Education$2,4321%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 34 | $45,908 |
| EMD Serono, Inc. | 30 | $21,403 |
| Pfizer | 11 | $18,936 |
| Seagen Inc. | 15 | $16,890 |
| Astellas Pharma US Inc | 15 | $15,729 |
| Merck | 9 | $12,876 |
| Merck Kgaa | 2 | $11,040 |
| Bayer | 7 | $10,370 |
| Astellas Pharma Global Development | 6 | $8,066 |
| Sanofi | 4 | $5,673 |
| Novartis | 3 | $5,094 |
| Myovant Sciences Inc. | 1 | $4,650 |
| Amgen | 1 | $3,570 |
| Immunomedics, Inc. | 1 | $2,475 |
| AstraZeneca | 1 | $2,398 |
| Eisai Inc. | 1 | $2,280 |
| AVEO Pharmaceuticals, Inc. | 2 | $2,185 |
| Exelixis Inc. | 1 | $1,980 |
| F. Hoffmann-la Roche AG | 4 | $1,772 |
| Janssen Scientific Affairs, LLC | 1 | $758 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$194,052 in reported general payments places this provider in the 90th percentile of 95 medical oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 122 | $1,719,994 |
| NubeqaDarolutamide | 45 | $745,317 |
| CabometyxCabozantinib S-Malate | 21 | $624,361 |
| Abiraterone Acetate | 304 | $501,736 |
| ErleadaApalutamide | 25 | $376,893 |
| OrgovyxRelugolix | 133 | $360,318 |
| InlytaAxitinib | 14 | $285,071 |
| LynparzaOlaparib | 11 | $108,876 |
| EliquisApixaban | 20 | $11,859 |
| PradaxaDabigatran Etexilate Mesylate | 12 | $2,259 |
| Prednisone | 225 | $819 |
| Bicalutamide | 29 | $400 |
| Tamsulosin Hcl | 26 | $301 |
| Alendronate Sodium | 29 | $293 |
| Oxybutynin Chloride | 17 | $170 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $15,729 | $1,719,994122 claims |
| BayerNubeqa | $10,370 | $745,31745 claims |
| Exelixis Inc.Cabometyx | $1,980 | $624,36121 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $758 | $501,736304 claims |
| PfizerInlyta, Eliquis | $18,936 | $296,93034 claims |
| AstraZenecaLynparza | $2,398 | $108,87611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 95 medical oncology providers in Virginia.
Other medical oncology in Falls Church
- Janakiraman SubramanianFairfax$562K
- Alexander SpiraFairfax$533K
- Robert DreicerCharlottesville$296K
- Roy BeveridgeFairfax$216K
- Kathleen HarndenFairfax$195K
- Nagla Abdel KarimFairfax$131K
- John McCartyRichmond$97K
- Keri MaherRichmond$96K
- Ryan GentzlerCharlottesville$62K
- Lauren MauroFairfax$53K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.